Samuele Takeshita: Scientific and Practical Aspects of Gene Therapy Access in Hemophilia and SCD
Samuele Takeshita, Head of Sales and Business Development at ELIXI International, shared a post on LinkedIn:
“A highly suggested reading to capture both the scientific and practical aspects of gene therapy access in hemophilia and sickle cell disease (SCD).
It explains how gene therapy science differs between viral vector‑based and ex vivo cell‑based approaches and their clinical implications.
In hemophilia, adeno‑associated viral (AAV) vectors deliver functional factor VIII or IX genes but can trigger inflammatory hepatotoxicity, requiring corticosteroid management.
In SCD, autologous hematopoietic stem cells are modified ex vivo (via lentiviral or CRISPR techniques) and reinfused after conditioning, providing durable functional hemoglobin but high acute toxicity risk.
Both approaches demonstrate durable efficacy, though long‑term safety data remain limited.”
Stay updated with Hemostasis Today.
-
Jun 7, 2026, 12:28Thrombosis in Cancer Patients: Why It Happens and How We Treat It Today
-
Jun 7, 2026, 12:01Addressing Real-World Challenges in Thrombosis Care Through Case-Based Learning – Thrombosis Canada
-
Jun 7, 2026, 11:46Zehraan Ibni Akbar: Transforming Laboratory Data into Clinical Decisions Through Platelet Disorder Recognition
-
Jun 7, 2026, 11:31Alice Zerbinati: Y-90 Radioembolization Expands Curative Options for Advanced Hepatocellular Carcinoma
-
Jun 7, 2026, 09:26Filimon Dagnew Bezabih: SNMMI Honors 18F-GP1 PET Imaging for Innovation in Thrombosis Detection
-
Jun 7, 2026, 06:57Chandran Nadarajan: Targeted Endovascular Thrombolysis Offers Organ-Saving Benefits in Vascular Occlusions
-
Jun 7, 2026, 05:50Sayan Koley: Lupus Anticoagulant – A Key Marker in Thrombosis Risk Assessment
-
Jun 7, 2026, 05:45Nicolas Hubacz: Watching a Heart Build Its Network
-
Jun 7, 2026, 05:40New Evidence Highlights the Urgent Need for Gender-Inclusive Bleeding Disorders Research – EHC